[Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
An 81-year-old man on chronic hemodialysis was referred to our hospital with urinary difficulty. Transperineal needle biopsy of a hard nodule in the prostate revealed moderately differentiated adenocarcinoma. He was diagnosed to have stage C prostate cancer. A standard dose of luteinizing hormone-releasing hormone (LH-RH) analogue, leuprorelin acetate (3.75 mg), was administered every 4 weeks for 15 months. No adverse effects were observed throughout the period. The clinical response to LH-RH analogue was excellent, with normalization of serum prostate-specific antigen level and relief of dysuria. Thus the standard dosage of LH-RH analogue is considered to be adequate for hemodialysis patients.
Mizusawa
H
H
Department of Urology, National Matsumoto Hospital.
Kontani
K
K
Okaneya
T
T
Yoneyama
T
T
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000150:complications / Q000628:therapy; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D006435:Renal Dialysis; D013739:Testosterone / Q000097:blood
D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone; D007986:Luteinizing Hormone; D016729:Leuprolide